» Articles » PMID: 36452504

Disrupting PTPRJ Transmembrane-mediated Oligomerization Counteracts Oncogenic Receptor Tyrosine Kinase FLT3 ITD

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Dec 1
PMID 36452504
Authors
Affiliations
Soon will be listed here.
Abstract

The receptor protein tyrosine phosphatase (RPTP) PTPRJ (also known as DEP-1) has been identified as a negative regulator of the receptor tyrosine kinase FLT3 signalling . The inactivation of the gene in mice expressing the constitutively active, oncogenic receptor tyrosine kinase FLT3 ITD aggravated known features of leukaemogenesis, revealing PTPRJ's antagonistic role. FLT3 ITD mutations resulting in constitutively kinase activity and cell transformation frequently occur in patients with acute myeloid leukaemia (AML). Thus, activation of PTPRJ could be used to abrogate oncogenic FLT3 signalling. The activity of PTPRJ is suppressed by homodimerization, which is mediated by transmembrane domain (TMD) interactions. Specific Glycine-to-Leucine mutations in the TMD disrupt oligomerization and inhibit the Epidermal Growth Factor Receptor (EGFR) and EGFR-driven cancer cell phenotypes. To study the effects of PTPRJ TMD mutant proteins on FLT3 ITD activity in cell lines, endogenous PTPRJ was inactivated and replaced by stable expression of PTPRJ TMD mutants. Autophosphorylation of wild-type and ITD-mutated FLT3 was diminished in AML cell lines expressing the PTPRJ TMD mutants compared to wild-type-expressing cells. This was accompanied by reduced FLT3-mediated global protein tyrosine phosphorylation and downstream signalling. Further, PTPRJ TMD mutant proteins impaired the proliferation and transformation of leukemic cells. Although PTPRJ's TMD mutant proteins showed impaired self-association, the specific phosphatase activity of immunoprecipitated proteins remained unchanged. In conclusion, this study demonstrates that the destabilization of PTPRJ TMD-mediated self-association increases the activity of PTPRJ and impairs FLT3 activity and FLT3-driven cell phenotypes of AML cells. Thus, disrupting the oligomerization of PTPRJ could prove a valuable therapeutic strategy to restrict oncogenic FLT3 activity in leukemic cells.

Citing Articles

Identifying Transmembrane Interactions in Receptor Protein Tyrosine Phosphatase Homodimerization and Heterodimerization.

Rizzo S, Thevenin D Methods Mol Biol. 2023; 2743:195-209.

PMID: 38147217 PMC: 10785008. DOI: 10.1007/978-1-0716-3569-8_13.


Promoting the activity of a receptor tyrosine phosphatase with a novel pH-responsive transmembrane agonist inhibits cancer-associated phenotypes.

Rizzo S, Sikorski E, Park S, Im W, Vasquez-Montes V, Ladokhin A Protein Sci. 2023; 32(9):e4742.

PMID: 37515426 PMC: 10461461. DOI: 10.1002/pro.4742.

References
1.
Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C . Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000; 96(12):3907-14. View

2.
Balavenkatraman K, Jandt E, Friedrich K, Kautenburger T, Pool-Zobel B, Ostman A . DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients. Oncogene. 2006; 25(47):6319-24. DOI: 10.1038/sj.onc.1209647. View

3.
Schnittger S, Bacher U, Haferlach C, Alpermann T, Kern W, Haferlach T . Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data. Genes Chromosomes Cancer. 2012; 51(10):910-24. DOI: 10.1002/gcc.21975. View

4.
Ostman A, Bohmer F . Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases. Trends Cell Biol. 2001; 11(6):258-66. DOI: 10.1016/s0962-8924(01)01990-0. View

5.
Maroc N, Rottapel R, Rosnet O, Marchetto S, Lavezzi C, Mannoni P . Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase. Oncogene. 1993; 8(4):909-18. View